Rowcaps |
---|
Rows 1-2: | For these findings, the specimen consists of tissues from both the testis and the epididymis. Therefore, the list of tissues comprising the specimen becomes the SPEC value for each contributing tissue, noted by a slash, as is found in the controlled terminology list. | Row 2: | For this finding, the base pathological process is inflammation, and is recorded in MISTRESC. The term "acute" is recorded in MICHRON using the controlled CHRNCTY codelist term ACUTE. | Row 3: | For this finding, the specimen consists of skeletal muscle. The base pathological process is degeneration/regeneration and is represented in MISTRESC. The term "Myofiber" is recorded in MIRESMOD (SUPPMI example). | Row 4: | This is an example of a reason why a microscopic evaluation of the mammary gland specimen was not performed. Note that MIORRES is null and MISTAT is "NOT DONE", the reason for the specimen not being evaluated is entered in MIREASND. | Row 5: | This shows an example of a record where the specimen contained no pathologic process. A record should be included for every scheduled specimen that was without pathology. The controlled NONNEO term "UNREMARKABLE" is recorded in MISTRESC. Note: There is no MIRESCAT for "UNREMARKABLE" as there is no finding. | Row 6: | In this record, the finding was the cause of death; therefore, MIDTHREL is "Y" (Yes). | Row 7: | The base pathological process is hyperplasia, recorded into MISTRESC from the NONNEO controlled terminology list. The modifiers "endometrial" and "cystic" are recorded in MIRESMOD (SUPPMI example). Note that the 2 values for MIRESMOD are separated by a semicolon, as required in Section 6.3.8. | Row 8: | For this finding, a mass identified as mass 1 (MISPID="MASS 1") is observed on the left ovary (MILAT = "LEFT"). This mass is considered benign (MIRESCAT). Note that MISTRESC contains controlled terminology for the tumor, which may include term(s) similar to characteristics and/or distribution as part of the base pathological process. | Row 9: | This is an example of a malignant mass (MISPID = "MASS 2"). The malignancy of the mass is recorded as part of the original result (MIORRES) as well as the controlled term in MIRESCAT. This finding was not the cause of death of the subject (MIDTHREL= "N"). Note that MISTRESC contains only the finding without modifiers. This record is linked to row 11 (via the MIGRPID value of 1) to relate the primary tumor with its metastasis in another tissue. The tumor origin described in MIORRES ("Primary") is associated to the MI records using the supplemental qualifier MIRESMOD (SUPPMI example). | Row 10: | This shows an example of a metastasis found in the uterus. The primary site for this tumor is unknown, and the sponsor applicant decided to include row 13 ("SITE, UNCERTAIN PRIMARY") to represent the source tumor. This record is related to rows 12 and 13 via the MIGRPID value of 2. | Row 11: | This finding describes a mass (MISPID="MASS 3") that is a metastasis of a primary tumor, which is recorded in the original result (MIORRES). This specific finding did not cause the death of the animal (MIDTHREL="N"). This record is linked to row 9 via the MIGRPID value of 1 to relate the metastasis to the finding at the primary site identified for the tumor. | Row 12: | This record illustrates another metastasis row for the lymphoma found in multiple sites. This record is related to rows 10 and 13 via the MIGRPID value of 2. | Row 13: | This record is an example of how to represent an unknown primary site for the lymphoma found in the uterus and vagina (row 11). The sponsor applicant decided to include a row to represent the base tumor (TFSPEC="SITE, UNCERTAIN PRIMARY") related to the metastasis row via the MIGRPID of 2, and defining it as the cause of death (MIDTHREL="Y"). Note: The use of "SITE, UNCERTAIN PRIMARY" is sponsorapplicant-specific; an alternative (based on how the data are collected) would be to exclude this row and only include rows for each site at which the tumor was found. | Rows 14-15: | These findings demonstrates an original result with modifiers, including a severity which is copied into MISEV. The base pathological process is entered into MISTRESC using the controlled terminology list and the remaining modifiers are recorded in MIRESMOD ("Mononuclear Cell" for line 14) and MIDISTR ("Multifocal" for line 15) in the SUPPMI example. | Rows 16-17: | These findings demonstrate the use of specimen location qualifiers of MIANTREG, MILAT, and MIDIR. | Row 18: | This finding demonstrates the use of finding qualifiers MICHRON, MIDISTR, and MIRESMOD, and the use of a semicolon to separate 2 terms in MIRESMOD (SUPPMI example). | Row 19: | This record is an example of an incidental malignant neoplasm in the liver that has not metastasized. The MIDTHREL is "N" because the tumor is incidental. | |
Dataset2 |
---|
Row | STUDYID | DOMAIN | USUBJID | MISEQ | MIGRPID | MISPID | MISTESTCDMITESTCD | MITEST | MIORRES | MISTRESC | MICHRON | MIDISTR | MIRESCAT | MISTAT | MIREASND | MISPEC | MIANTREG | MISPCCND | MISPCUFL | MILAT | MIDIR | MISEV | MIDTHREL | MIDTC | MIDY |
---|
1 | 123 | MI | 123-01 | 1 | MIEXAM |
|
| GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination | Amyloidosis, grade 2 | AMYLOID |
|
| NON-NEOPLASTIC |
|
| TESTIS/EPIDIDYMIS |
|
|
|
|
| MILD |
| 2015-10-27 | 365 | 2 | 123 | MI | 123-01 | 2 | MIEXAM |
|
| GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination | Inflammation, acute, grade 2 | INFLAMMATION | ACUTE |
| NON-NEOPLASTIC |
|
| TESTIS/EPIDIDYMIS |
|
|
|
|
| MILD |
| 2015-10-27 | 365 | 3 | 123 | MI | 123-01 | 3 | MIEXAM |
|
| GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination | Degeneration/regeneration, myofiber, grade 4 | DEGENERATION/ REGENERATION |
|
| NON-NEOPLASTIC |
|
| MUSCLE, SKELETAL |
|
|
|
|
| MARKED |
| 2015-10-27 | 365 | 4 | 123 | MI | 123-01 | 4 | MIEXAM |
|
| GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination |
|
|
|
|
| NOT DONE | Tissue not present for histologic examination no glandular tissue in section | GLAND, MAMMARY |
|
|
|
|
|
|
| 2015-10-27 | 365 | 5 | 123 | MI | 123-01 | 5 | MIEXAM |
|
| GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination | Normal | UNREMARKABLE |
|
|
|
|
| GLAND, PARATHYROID |
|
|
|
|
|
|
| 2015-10-27 | 365 | 6 | 123 | MI | 123-02 | 6 | MIEXAM |
|
| GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination | Inflammation, meninges, grade 5 | INFLAMMATION |
|
| NON-NEOPLASTIC |
|
| BRAIN |
|
|
|
|
| SEVERE | Y | 2015-05-15 | 200 | 7 | 123 | MI | 123-03 | 7 | MIEXAM |
|
| GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination | Hyperplasia, endometrial cystic, grade 3 | HYPERPLASIA |
|
| NON-NEOPLASTIC |
|
| UTERUS |
|
|
|
|
| MODERATE |
| 2015-10-27 | 365 | 8 | 123 | MI | 123-03 | 8 |
| MASS 1 | MIEXAM | GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination | Adenoma: tubulostromal (benign neoplasm), left | ADENOMA, TUBULOSTROMAL, BENIGN |
|
| BENIGN |
|
| OVARY |
|
|
| LEFT |
|
| N | 2015-10-27 | 365 | 9 | 123 | MI | 123-03 | 9 | 1 | MASS 2 | MIEXAM | GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination | Sarcoma: endometrial stromal (malignant neoplasm), Primary | STROMAL SARCOMA, ENDOMETRIAL, MALIGNANT |
|
| MALIGNANT |
|
| UTERUS |
|
|
|
|
|
| N | 2015-10-27 | 365 | 10 | 123 | MI | 123-03 | 10 | 2 | MIEXAM |
| GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination | Lymphoma: metastasis | LYMPHOMA, MALIGNANT |
|
| METASTATIC |
|
| UTERUS |
|
|
|
|
|
| U | 2015-10-27 | 365 | 11 | 123 | MI | 123-03 | 11 | 1 | MASS 3 | MIEXAM | GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination | Sarcoma: metastasis; Uterus was the primary site | SARCOMA, MALIGNANT |
|
| METASTATIC |
|
| VAGINA |
|
|
|
|
|
| N | 2015-10-27 | 365 | 12 | 123 | MI | 123-03 | 12 | 2 | MIEXAM |
| GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination | Lymphoma: metastasis | LYMPHOMA, MALIGNANT |
|
| METASTATIC |
|
| VAGINA |
|
|
|
|
|
| U | 2015-10-27 | 365 | 13 | 123 | MI | 123-03 | 13 | 2 | MIEXAM |
| GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination | Lymphoma: multicentric | LYMPHOMA, MALIGNANT |
|
| MALIGNANT |
|
| SITE, UNCERTAIN PRIMARY |
|
|
|
|
|
| Y | 2015-10-27 | 365 | 14 | 123 | MI | 123-04 | 14 | MIEXAM |
|
| GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination | Infiltrate, mononuclear cell, grade 1 | INFILTRATE |
|
| NON-NEOPLASTIC |
|
| MENINGES |
|
|
|
|
| MINIMAL |
| 2015-10-27 | 365 | 15 | 123 | MI | 123-04 | 15 | MIEXAM |
|
| GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination | Atrophy, multifocal, grade 2 | ATROPHY |
| MULTIFOCAL | NON-NEOPLASTIC |
|
| TESTIS |
|
|
|
|
| MILD |
| 2015-10-27 | 365 | 16 | 123 | MI | 123-04 | 16 | MIEXAM |
|
| GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination | Intra-alveolar hemorrhage, right, grade 2 | HEMORRHAGE |
|
| NON-NEOPLASTIC |
|
| LUNG | CRANIAL LOBE |
|
| RIGHT |
| MILD |
| 2015-10-27 | 365 | 17 | 123 | MI | 123-04 | 17 | MIEXAM |
|
| GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination | Cyst, right, anterior | CYST |
|
| NON-NEOPLASTIC |
|
| KIDNEY |
|
|
| RIGHT | ANTERIOR |
|
| 2015-10-27 | 365 | 18 | 123 | MI | 123-05 | 18 | MIEXAM |
|
| GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination | Inflammation, moderate, chronic, multifocal, mucosal, forestomach, grade 3 | INFLAMMATION | CHRONIC | MULTIFOCAL | NON-NEOPLASTIC |
|
| STOMACH |
|
|
|
|
| MODERATE |
| 2015-10-27 | 365 | 19 | 123 | MI | 123-06 | 19 | MIEXAM |
|
| GHISTXQL | General Histopathologic Exam, QualMicroscopic Examination | Hepatocellular carcinoma (malignant neoplasm without metastasis), incidental | CARCINOMA, HEPATOCELLULAR, MALIGNANT |
|
| MALIGNANT |
|
| LIVER |
|
|
|
|
|
| N | 2015-10-07 | 345 |
|
|